Patents by Inventor Claude Barberis

Claude Barberis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES
    Publication number: 20230357270
    Abstract: Provided herein are compounds and compositions thereof for activating nuclear factor erythroid 2-related factor 2 (Nrf2) for treating red blood cell diseases and inflammatory diseases.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 9, 2023
    Inventors: Claude Barberis, George Karageorge, John Jurcak, Kristen Terranova
  • COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS
    Publication number: 20220396588
    Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).
    Type: Application
    Filed: February 9, 2022
    Publication date: December 15, 2022
    Applicant: Genzyme Corporation
    Inventors: John L. Kane, JR., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Shum, Linli Wei
  • Colony stimulating factor-1 receptor (CSF-1R) inhibitors
    Patent number: 11274108
    Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: March 15, 2022
    Assignee: GENZYME CORPORATION
    Inventors: John L. Kane, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
  • COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS
    Publication number: 20190016707
    Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).
    Type: Application
    Filed: July 19, 2016
    Publication date: January 17, 2019
    Inventors: John L. KANE, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
  • Substituted thieno[2,3-c]pyrazoles, process for preparing them, compositions containing them, and use thereof
    Patent number: 7884123
    Abstract: Compounds of formula (I), wherein R1 and R3 have the meanings given in the description, said compounds being in all isomeric forms; and salts thereof; processes for the preparation of the compounds and intermediates; compositions containing them, and the use thereof as medicaments, particularly as anti-cancer agents.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: February 8, 2011
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Christophe Carry, Gilles Doerflinger, Antony Bigot, Dominique Barbalat-Damour, François Clerc, Arielle Genevois-Borella, Baptiste Ronan, Hervé Minoux, Claude Barberis, Yves Janin
  • Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof
    Patent number: 7595320
    Abstract: The present invention concerns hydrazinocarbonyl-thieno[2,3-c]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: September 29, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Claude Barberis, Jean-Christophe Carry, Gilles Doerflinger, Dominique Barbalat-Damour, Francois Clerc, Herve Minoux
  • Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof
    Publication number: 20080146542
    Abstract: The present invention concerns hydrazinocarbonyl-thieno[2,3-c]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.
    Type: Application
    Filed: August 29, 2007
    Publication date: June 19, 2008
    Applicant: Aventis Pharma S.A.
    Inventors: Claude BARBERIS, Jean-Christophe CARRY, Gilles DOERFLINGER, Dominique BARBALAT-DAMOUR, Francois CLERC, Herve MINOUX
  • Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof
    Publication number: 20080058402
    Abstract: Compounds of formula (I), wherein R1 and R3 have the meanings given in the description, said compounds being in all isomeric forms; and salts thereof; processes for the preparation of the compounds and intermediates; compositions containing them, and the use thereof as medicaments, particularly as anti-cancer agents.
    Type: Application
    Filed: May 23, 2007
    Publication date: March 6, 2008
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Jean-Christophe CARRY, Gilles DOERFLINGER, Antony BIGOT, Dominique BARBALAT-DAMOUR, Francois CLERC, Arielle GENEVOIS-BORELLA, Baptiste RONAN, Herve MINOUX, Claude BARBERIS, Yves JANIN
  • Indazole compounds
    Publication number: 20070282101
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Application
    Filed: April 2, 2007
    Publication date: December 6, 2007
    Inventors: Anna Ericsson, Andrew Burchat, Kristine Frank, David Calderwood, Lily Abbott, Maria Argiriadi, David Borhani, Kevin Cusack, Richard Dixon, Thomas Gordon, Kelly Mullen, Robert Talanian, Xiaoyun Wu, Xiaolei Zhang, Lu Wang, Biqin Li, Claude Barberis, Neil Wishart
  • Kinase inhibitors as therapeutic agents
    Publication number: 20060074102
    Abstract: A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
    Type: Application
    Filed: May 13, 2005
    Publication date: April 6, 2006
    Inventors: Kevin Cusack, Jose-Andres Salmeron-Garcia, Thomas Gordon, Claude Barberis, Hamish Allen, Agniezka Bischoff, Anna Ericsson, Michael Friedman, Dawn George, Gregory Roth, Robert Talanian, Christine Thomas, Grier Wallace, Neil Wishart, Zhengtian Yu